دورية أكاديمية
Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study
| العنوان: | Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study |
|---|---|
| المؤلفون: | Fontán-Vela, Mario, Hernando, Victoria, Olmedo, Carmen, Coma, Ermengol, Martínez, Montse, Moreno-Perez, David, Lorusso, Nicola, Vázquez Torres, María, Barbas del Buey, José Francisco, Roig-Sena, Javier, Pastor, Eliseo, Galmés Truyols, Antònia, Artigues Serra, Francisca, Sancho Martínez, Rosa María, Latasa Zamalloa, Pello, Pérez Martínez, Olaia, Vázquez Estepa, Ana, García Rojas, Amós José, Barreno Estévez, Ana Isabel, Sánchez-Migallón Naranjo, Alonso, Pérez Martín, Jaime Jesús, Peces Jiménez, Pilar, Morales Romero, Raquel, Castilla, Jesús, García Cenoz, Manuel, Huerta Huerta, Marta, Boone, An Lieve Dirk, Macías Ortiz, María José, Álvarez Río, Virginia, Rodríguez Recio, María Jesús, Merino Díaz, María, Berradre Sáenz, Belén, Villegas-Moreno, María Teresa, Limia, Aurora, Diaz, Asuncion, Monge, Susana, Rodrigo, José Antonio Lluch, Juaneda, Juan, Malonda, Rosa Carbo, Mendioroz, Jacobo, Farran, Joan Colom, Carril, Fernando González, Echevarría, Lorea Oscoz, Barros, María Teresa Otero, Gaiche, Nuria Suárez, Martínez, José Angélica Gómez, Bastante, Borja Alcázar, Santos, Rocío Sánchez, Sanjurjo, Lucía Fuster, del Carmen Pacheco Martínez, María |
| المصدر: | Clinical Infectious Diseases ; volume 78, issue 2, page 476-483 ; ISSN 1058-4838 1537-6591 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2023 |
| الوصف: | Background With more than 7500 cases reported since April 2022, Spain has experienced the highest incidence of mpox in Europe. From 12 July onward, the modified vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure prophylaxis for those receiving pre-exposure prophylaxis for human immunodeficiency virus (HIV-PrEP). Our aim was to assess the effectiveness of 1 dose of MVA-BN vaccine as pre-exposure prophylaxis against mpox virus (MPXV) infection in persons on HIV-PrEP. Methods National retrospective cohort study between 12 July and 12 December 2022. Individuals aged ≥18 years receiving HIV-PrEP as of 12 July with no previous MPXV infection or vaccination were eligible. Each day, we matched individuals receiving a first dose of vaccine and unvaccinated controls of the same age and region. We used a Kaplan–Meier estimator, calculated risk ratios (RR) and vaccine effectiveness (VE = [1 − RR]x100). Results We included 5660 matched pairs, with a median follow-up of 62 days (interquartile range, 24–97). Mpox cumulative incidence was 5.6 per 1000 (25 cases) in unvaccinated and 3.5 per 1000 (18 cases) in vaccinated. No effect was found during days 0–6 post-vaccination (VE, −38.3; 95% confidence interval [CI], −332.7 to 46.4), but VE was 65% at ≥7 days (95% CI, 22.9 to 88.0) and 79% at ≥14 days (95% CI, 33.3 to 100.0) post-vaccination. Conclusions One dose of MVA-BN vaccine offered protection against mpox in most-at-risk population shortly after the vaccination. Further studies need to assess the VE of a second dose and the duration of protection over time. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/cid/ciad645 |
| DOI: | 10.1093/cid/ciad645/54948558/ciad645.pdf |
| الإتاحة: | https://doi.org/10.1093/cid/ciad645Test https://academic.oup.com/cid/article-pdf/78/2/476/56697890/ciad645.pdfTest |
| حقوق: | https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.76ECC9E8 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/cid/ciad645 |
|---|